Scarica l'app Stockscreener
2.18
5.22%
-0.12
Dopo l'orario di chiusura:
2.22
0.04
+1.83%
Century Therapeutics Inc Borsa (IPSC) Ultime notizie
Century Therapeutics SVP Carr sells $3,691 in company stock By Investing.com - Investing.com Australia
Century Therapeutics executive Gregory Russotti sells $5,767 in stock By Investing.com - Investing.com India
Century Therapeutics (IPSC) executive sells shares to cover RSU tax withholding - Stock Titan
Tax-related share sale by Century Therapeutics (IPSC) SVP Carr - Stock Titan
Century Therapeutics (IPSC) CEO reports 13,849-share tax withholding on RSU vesting - Stock Titan
Century Therapeutics (IPSC) CSO reports tax withholding of shares and restated holdings - Stock Titan
Here's Why We're Watching Century Therapeutics' (NASDAQ:IPSC) Cash Burn Situation - Yahoo Finance
Century Therapeutics (IPSC) director Alessandro Riva granted 74,000 stock options - Stock Titan
Director Daphne Quimi receives 74,000 stock options at Century Therapeutics (NASDAQ: IPSC) - Stock Titan
Century Therapeutics (IPSC) director receives grant of 74,000 stock options - Stock Titan
Century Therapeutics (IPSC) director granted 74,000 stock options at $2.24 - Stock Titan
Century Therapeutics (IPSC) awards 74,000 stock options to director Kimberly Blackwell - Stock Titan
Century Therapeutics (IPSC) shareholders back higher authorized shares and board slate - Stock Titan
Insider sale notice for IPSC (NASDAQ: IPSC) — 2,584 shares planned; prior disposals listed - Stock Titan
Century Therapeutics (IPSC) Reports Positive Preclinical Results For Diabetes Cell Therapy CNTY-813 - Insider Monkey
Lupus Nephritis Clinical Trial Landscape Becomes Increasingly Crowded with 30+ Pharma Companies | DelveInsight - GlobeNewswire Inc.
Mizuho Securities Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $8 - Moomoo
Century Therapeutics (IPSC) executive logs small automatic share sale for taxes - Stock Titan
Century Therapeutics (IPSC) SVP’s automatic 249-share sale covers RSU tax withholding - Stock Titan
Century Therapeutics (NASDAQ: IPSC) CEO has 463 shares withheld for RSU taxes - Stock Titan
Century Therapeutics, Inc. (IPSC) Presents at American Diabetes Association (ADA) 86th Scientific SessionsSlideshow (NASDAQ:IPSC) 2026-06-09 - Seeking Alpha
Century Therapeutics, Inc. (IPSC) Stock Price, News, Quote & History - Yahoo! Finance Canada
Century Therapeutics Advances CNTY-813 Diabetes Cell Therapy - TipRanks
Century Therapeutics presents preclinical data on diabetes therapy By Investing.com - Investing.com Canada
Century Therapeutics presents preclinical data on diabetes therapy - Investing.com
Century Therapeutics (NASDAQ: IPSC) details CNTY-813 diabetes cell therapy data - Stock Titan
New CNTY-813 Preclinical Data Demonstrate Durable Glucose - GlobeNewswire
IPSC (NASDAQ: IPSC) Form 144: proposed sale of vested common shares - Stock Titan
Number of shareholders of Century Therapeutics, Inc. – NASDAQ:IPSC - TradingView
Century Therapeutics (IPSC) Q1 2026 Earnings: Narrower Loss Beats Estimates as Clinical Pipeline Advances - newsline.com
Century Therapeutics Price Target Announced at $8.00/Share by Mizuho - Moomoo
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Mizuho Initiates Century Therapeutics at Outperform - Moomoo
Century Therapeutics (IPSC) Inches Higher, Approaches Key Resistance LevelVWAP Deviation - newsline.com
This GE Aerospace analyst begins coverage on a bullish note; here are top 5 initiations for Wednesday - MSN
This GE Aerospace Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Mizuho Initiates Century Therapeutics at Outperform With $8 Price Target - marketscreener.com
Century Therapeutics Initiated at Outperform by Mizuho - Moomoo
Mizuho initiates Century Therapeutics stock coverage at Outperform - Investing.com
Mizuho initiates Century Therapeutics stock coverage at Outperform By Investing.com - Investing.com Canada
Mizuho initiates coverage of Century Therapeutics (IPSC) with outperform recommendation - MSN
Century Therapeutics (IPSC) Holds Near Support After Modest DeclineChart Pattern Alerts - The Legal Advocate
Century Advances Diabetes Cell Therapy Toward Human Trials - MyChesCo
IPSC Stock Price, Quote & Chart | CENTURY THERAPEUTICS INC (NASDAQ:IPSC) - ChartMill
Century Therapeutics Q1 2026 Earnings: EPS Surpasses Estimates as Pipeline Progress ContinuesRising Community Picks - Newser
IPSC (NASDAQ: IPSC) resale supplement substitutes Point72 with SILV Fund - Stock Titan
Analysts Are Bullish on Top Healthcare Stocks: Invivyd (IVVD), Century Therapeutics (IPSC) - The Globe and Mail
Century Therapeutics (IPSC) CEO has 31,172 shares withheld to cover RSU tax obligations - Stock Titan
H.C. Wainwright Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $5 - Moomoo
Despite Fast-paced Momentum, Century Therapeutics (IPSC) Is Still a Bargain Stock - MSN
Century Therapeutics (IPSC) Stock: Slides -1.68%, Support at $2.22 2026-05-15Professional Trade Ideas - newser.com
Point72 group reports 5.96M-share stake in Century Therapeutics (IPSC) - Stock Titan
RTW Investments and R. Wong report 7.1% stake in Century Therapeutics (IPSC) - Stock Titan
Analysts Are Bullish on These Healthcare Stocks: Century Therapeutics (IPSC), Lucid Diagnostics (LUCD) - The Globe and Mail
Century Therapeutics 1Q Research and Development Expenses $17.1M >IPSC - Moomoo
Versant Venture Management, LLC's Century Therapeutics Inc(IPSC) Holding History - GuruFocus
Corbus Pharmaceuticals Appoints Pharma Industry Veteran Brent Pfeiffenberger to Board of Directors - Investing News Network
Piper Sandler Maintains Century Therapeutics(IPSC.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Century Therapeutics (IPSC) Gains +1.80% — Support Holds at $2.20 2026-05-14Long Setup - newser.com
Century Therapeutics, Inc. 2026 Q1 10-Q Report: Financials, Risk Factors, and Forward-Looking Statements - Minichart
Century Therapeutics Reports First Quarter Financial Results and Business Updates - Investing News Network
Century Therapeutics Reports Q1 2026 Financial Results, Advances iPSC-Derived Diabetes and Cancer Therapies, Cash Runway to 2029 - Minichart
Century Therapeutics Q1 Earnings Beat Expectations - Intellectia AI
Century Therapeutics reports Q1 net loss $21.6M, cash runway into Q1 2029 - TradingView
Century Therapeutics 1Q 2026: Revenue ($22.26M), Net income ($21.65M), EPS ($0.11) — 10-Q Summary - TradingView
Century Therapeutics posts smaller-than-expected Q1 net loss on lower R&D spend - TradingView
Century Therapeutics (NASDAQ: IPSC) swings to Q1 2026 loss as prior collaboration revenue rolls off - Stock Titan
1.27%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):